MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy. J Nucl Med. 2025 (in press).
Kayal G, Barbosa N, Marín C, Ferrer L, Fragoso-Negrín J-A, Grosev D, Gupta S, Hidayati N, Moalosi T, Poli G, Thakral P, Tsapaki V, Vauclin S, Vergara-Gil A, Knoll P, Hobbs R, Bardiès M Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. J Nucl Med. 2024;65(1):125-131. doi:10.2967/jnumed.122.265340
Poty S, Ordas L, Dekempeneer Y, Parach A, Navarro L, Santens F, Dumauthioz N, Bardiès M, Lahoutte T, D'Huyvetter M, Pouget J-P Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting. J Nucl Med. 2024;65(10):1564-1570. doi:10.2967/jnumed.124.267624
Pouget J-P, Chan T, Galluzzi L, Constanzo J Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. Trends Cancer. 2023;9(11):968-981. doi:10.1016/j.trecan.2023.07.014
Idrissou M, Pichard A, Tee B, Kibedi T, Poty S, Pouget J-P Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics. 2021;13(7):980. doi:10.3390/pharmaceutics13070980
Institut de Recherche en Cancérologie de
